RESUMO
BACKGROUND: A fundamental challenge in quantitation of biomolecules for cancer biomarker discovery is owing to the heterogeneous nature of human biospecimens. Although this issue has been a subject of discussion in cancer genomic studies, it has not yet been rigorously investigated in mass spectrometry based proteomic and metabolomic studies. Purification of mass spectometric data is highly desired prior to subsequent analysis, e.g., quantitative comparison of the abundance of biomolecules in biological samples. METHODS: We investigated topic models to computationally analyze mass spectrometric data considering both integrated peak intensities and scan-level features, i.e., extracted ion chromatograms (EICs). Probabilistic generative models enable flexible representation in data structure and infer sample-specific pure resources. Scan-level modeling helps alleviate information loss during data preprocessing. We evaluated the capability of the proposed models in capturing mixture proportions of contaminants and cancer profiles on LC-MS based serum proteomic and GC-MS based tissue metabolomic datasets acquired from patients with hepatocellular carcinoma (HCC) and liver cirrhosis as well as synthetic data we generated based on the serum proteomic data. RESULTS: The results we obtained by analysis of the synthetic data demonstrated that both intensity-level and scan-level purification models can accurately infer the mixture proportions and the underlying true cancerous sources with small average error ratios (<7 %) between estimation and ground truth. By applying the topic model-based purification to mass spectrometric data, we found more proteins and metabolites with significant changes between HCC cases and cirrhotic controls. Candidate biomarkers selected after purification yielded biologically meaningful pathway analysis results and improved disease discrimination power in terms of the area under ROC curve compared to the results found prior to purification. CONCLUSIONS: We investigated topic model-based inference methods to computationally address the heterogeneity issue in samples analyzed by LC/GC-MS. We observed that incorporation of scan-level features have the potential to lead to more accurate purification results by alleviating the loss in information as a result of integrating peaks. We believe cancer biomarker discovery studies that use mass spectrometric analysis of human biospecimens can greatly benefit from topic model-based purification of the data prior to statistical and pathway analyses.
Assuntos
Biomarcadores Tumorais/sangue , Espectrometria de Massas/estatística & dados numéricos , Neoplasias/sangue , Proteômica/métodos , Carcinoma Hepatocelular/sangue , Carcinoma Hepatocelular/genética , Humanos , Cirrose Hepática/sangue , Cirrose Hepática/genética , Neoplasias Hepáticas/sangue , Neoplasias Hepáticas/genética , Metabolômica , Neoplasias/genéticaRESUMO
Associating changes in protein levels with the onset of cancer has been widely investigated to identify clinically relevant diagnostic biomarkers. In the present study, we analyzed sera from 205 patients recruited in the United States and Egypt for biomarker discovery using label-free proteomic analysis by LC-MS/MS. We performed untargeted proteomic analysis of sera to identify candidate proteins with statistically significant differences between hepatocellular carcinoma (HCC) and patients with liver cirrhosis. We further evaluated the significance of 101 proteins in sera from the same 205 patients through targeted quantitation by MRM on a triple quadrupole mass spectrometer. This led to the identification of 21 candidate protein biomarkers that were significantly altered in both the United States and Egyptian cohorts. Among the 21 candidates, ten were previously reported as HCC-associated proteins (eight exhibiting consistent trends with our observation), whereas 11 are new candidates discovered by this study. Pathway analysis based on the significant proteins reveals upregulation of the complement and coagulation cascades pathway and downregulation of the antigen processing and presentation pathway in HCC cases versus patients with liver cirrhosis. The results of this study demonstrate the power of combining untargeted and targeted quantitation methods for a comprehensive serum proteomic analysis, to evaluate changes in protein levels and discover novel diagnostic biomarkers. All MS data have been deposited in the ProteomeXchange with identifier PXD001171 (http://proteomecentral.proteomexchange.org/dataset/PXD001171).
Assuntos
Carcinoma Hepatocelular/metabolismo , Cromatografia Líquida/métodos , Neoplasias Hepáticas/metabolismo , Proteômica/métodos , Espectrometria de Massas em Tandem/métodos , Feminino , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
Defining clinically relevant biomarkers for early stage hepatocellular carcinoma (HCC) in a high-risk population of cirrhotic patients has potentially far-reaching implications for disease management and patient health. Changes in glycan levels have been associated with the onset of numerous diseases including cancer. In the present study, we used liquid chromatography coupled with electrospray ionization mass spectrometry (LC-ESI-MS) to analyze N-glycans in sera from 183 participants recruited in Egypt and the U.S. and identified candidate biomarkers that distinguish HCC cases from cirrhotic controls. N-Glycans were released from serum proteins and permethylated prior to the LC-ESI-MS analysis. Through two complementary LC-ESI-MS quantitation approaches, global profiling and targeted quantitation, we identified 11 N-glycans with statistically significant differences between HCC cases and cirrhotic controls. These glycans can further be categorized into four structurally related clusters, matching closely with the implications of important glycosyltransferases in cancer progression and metastasis. The results of this study illustrate the power of the integrative approach combining complementary LC-ESI-MS based quantitation approaches to investigate changes in N-glycan levels between HCC cases and patients with liver cirrhosis.
Assuntos
Biomarcadores Tumorais/sangue , Carcinoma Hepatocelular/diagnóstico , Cirrose Hepática/sangue , Neoplasias Hepáticas/diagnóstico , Polissacarídeos/sangue , Carcinoma Hepatocelular/sangue , Carcinoma Hepatocelular/etiologia , Cromatografia Líquida , Egito , Perfilação da Expressão Gênica/métodos , Humanos , Cirrose Hepática/complicações , Neoplasias Hepáticas/sangue , Neoplasias Hepáticas/etiologia , Espectrometria de Massas , Estados UnidosRESUMO
Fecal microbiota transplantation (FMT) is highly effective in recurrent Clostridioides difficile infection (CDI); increasing evidence supports FMT in severe or fulminant Clostridioides difficile infection (SFCDI). However, the multifactorial mechanisms that underpin the efficacy of FMT are not fully understood. Systems biology approaches using high-throughput technologies may help with mechanistic dissection of host-microbial interactions. Here, we have undertaken a deep phenomics study on four adults receiving sequential FMT for SFCDI, in which we performed a longitudinal, integrative analysis of multiple host factors and intestinal microbiome changes. Stool samples were profiled for changes in gut microbiota and metabolites and blood samples for alterations in targeted epigenomic, metabonomic, glycomic, immune proteomic, immunophenotyping, immune functional assays, and T-cell receptor (TCR) repertoires, respectively. We characterised temporal trajectories in gut microbial and host immunometabolic data sets in three responders and one non-responder to sequential FMT. A total of 562 features were used for analysis, of which 78 features were identified, which differed between the responders and the non-responder. The observed dynamic phenotypic changes may potentially suggest immunosenescent signals in the non-responder and may help to underpin the mechanisms accompanying successful FMT, although our study is limited by a small sample size and significant heterogeneity in patient baseline characteristics. Our multi-omics integrative longitudinal analytical approach extends the knowledge regarding mechanisms of efficacy of FMT and highlights preliminary novel signatures, which should be validated in larger studies.
Assuntos
Infecções por Clostridium/terapia , Transplante de Microbiota Fecal , Idoso , Idoso de 80 Anos ou mais , Animais , Anticorpos Neutralizantes/metabolismo , Toxinas Bacterianas/imunologia , Chlorocebus aethiops , Infecções por Clostridium/imunologia , Infecções por Clostridium/microbiologia , Análise por Conglomerados , Fezes/microbiologia , Feminino , Microbioma Gastrointestinal , Genômica , Humanos , Imunossenescência , Masculino , Pessoa de Meia-Idade , Filogenia , Receptores de Antígenos de Linfócitos T/metabolismo , Fatores de Tempo , Resultado do Tratamento , Células VeroRESUMO
Background: Metabolomics plays an important role in providing insight into the etiology and mechanisms of hepatocellular carcinoma (HCC). This is accomplished by a comprehensive analysis of patterns involved in metabolic alterations in human specimens. This study compares the levels of plasma metabolites in HCC cases versus cirrhotic patients and evaluates the ability of candidate metabolites in distinguishing the two groups. Also, it investigates the combined use of metabolites and clinical covariates for detection of HCC in patients with liver cirrhosis.Methods: Untargeted analysis of metabolites in plasma from 128 subjects (63 HCC cases and 65 cirrhotic controls) was conducted using gas chromatography coupled to mass spectrometry (GC-MS). This was followed by targeted evaluation of selected metabolites. LASSO regression was used to select a set of metabolites and clinical covariates that are associated with HCC. The performance of candidate biomarkers in distinguishing HCC from cirrhosis was evaluated through a leave-one-out cross-validation based on area under the receiver operating characteristics (ROC) curve.Results: We identified 11 metabolites and three clinical covariates that differentiated HCC cases from cirrhotic controls. Combining these features in a panel for disease classification using support vector machines (SVM) yielded better area under the ROC curve compared with alpha-fetoprotein (AFP).Conclusions: This study demonstrates the combination of metabolites and clinical covariates as an effective approach for early detection of HCC in patients with liver cirrhosis.Impact: Further investigation of these findings may improve understanding of HCC pathophysiology and possible implication of the metabolites in HCC prevention and diagnosis. Cancer Epidemiol Biomarkers Prev; 26(5); 675-83. ©2016 AACR.
Assuntos
Biomarcadores Tumorais/sangue , Carcinoma Hepatocelular/sangue , Neoplasias Hepáticas/sangue , Adulto , Idoso , Carcinoma Hepatocelular/diagnóstico , Feminino , Humanos , Cirrose Hepática/sangue , Cirrose Hepática/diagnóstico , Neoplasias Hepáticas/diagnóstico , Masculino , Metabolômica/métodos , Pessoa de Meia-Idade , Sensibilidade e EspecificidadeRESUMO
Studies associating changes in the levels of multiple biomolecules including proteins, glycans, glycoproteins, and metabolites with the onset of cancer have been widely investigated to identify clinically relevant diagnostic biomarkers. Advances in liquid or gas chromatography mass spectrometry (LC-MS, GC-MS) have enabled high-throughput qualitative and quantitative analysis of these biomolecules. While results from separate analyses of different biomolecules have been reported widely, the mutual information obtained by partly or fully combining them has been relatively unexplored. In this study, we investigate integrative analysis of proteins, N-glycans, and metabolites to take advantage of complementary information to improve the ability to distinguish cancer cases from controls. Specifically, support vector machine-recursive feature elimination algorithm is utilized to select a panel of proteins, N-glycans, and metabolites based on LC-MS and GC-MS data previously acquired by the analysis of blood samples from two cohorts in a liver cancer study. Improved performances are observed by integrative analysis compared to separate proteomic, glycomic, and metabolomic studies in distinguishing liver cancer cases from patients with liver cirrhosis.
Assuntos
Biomarcadores/análise , Biologia Computacional/métodos , Neoplasias/diagnóstico , Máquina de Vetores de Suporte , Diagnóstico Diferencial , Humanos , Cirrose Hepática , Neoplasias Hepáticas , Neoplasias/química , Neoplasias/metabolismo , Sensibilidade e EspecificidadeRESUMO
Liquid chromatography coupled with mass spectrometry (LC-MS) has been widely used for profiling protein expression levels. This chapter is focused on LC-MS data preprocessing, which is a crucial step in the analysis of LC-MS based proteomics. We provide a high-level overview, highlight associated challenges, and present a step-by-step example for analysis of data from LC-MS based untargeted proteomic study. Furthermore, key procedures and relevant issues with the subsequent analysis by multiple reaction monitoring (MRM) are discussed.
Assuntos
Proteoma , Proteômica/métodos , Cromatografia Líquida/métodos , Interpretação Estatística de Dados , Processamento Eletrônico de Dados , Espectrometria de Massas/métodosRESUMO
Studies associating changes in the levels of glycans and proteins with the onset of cancer have been widely investigated to identify clinically relevant diagnostic biomarkers. Advances in liquid chromatography mass spectrometry (LC-MS) have enabled high-throughput identification and quantitative analysis of these biomolecules. While results from separate analyses of glycans and proteins have been reported widely, the mutual information obtained by combining the two has been relatively unexplored. In this study, we investigate integrative analysis of glycans and proteins to take advantage complementary information to improve the ability to distinguish cancer cases from controls. Specifically, SVM-RFE algorithm is utilized to select a panel of N-glycans and proteins from LC-MS data previously acquired by analysis of sera from two cohorts in a liver cancer study. Improved performances are observed by integrative analysis compared to separate glycomic and proteomic studies in distinguishing liver cancer cases from patients with liver cirrhosis.